OBJECTIVE: Serum antibodies against the glial potassium channel KIR4.1 are found in a subpopulation of multiple sclerosis (MS) patients. Little is known about the expression of KIR4.1 in human normal brain tissue and in MS lesions. METHODS: We analyzed the expression pattern of KIR4.1 in normal brain tissue and MS lesions of the subcortical white matter by immunohistochemistry. Markers of related glial proteins, myelin, and inflammatory cells were analyzed in parallel. RESULTS: KIR4.1 is expressed in oligodendrocytes and astrocytes in the adult human brain. In oligodendrocytes, KIR4.1 appears as a homotetramer channel, in astrocytes as homo- and heterotetramer channels together with KIR5.1. In acute MS lesions, KIR4.1 immunoreactivity (IR) was differentially lost on periplaque oligodendrocytes and perivascular astrocytes. In part of acute lesions, complement activation, apoptotic KIR4.1(+) glial cells, and phagocytes containing KIR4.1(+) fragments accompanied loss of glial KIR4.1 IR. Periplaque reactive astrocytes showed enhanced IR for both KIR4.1 and KIR5.1. In chronic active MS lesions, apart from a general loss of oligodendrocytes in the demyelinated area, we observed a decrease of astroglial KIR4.1 but not glial fibrillary acidic protein IR. In chronic inactive and remyelinating MS lesions, KIR4.1 IR was restored on astrocytes and found in a subset of presumably new myelinating oligodendrocytes. INTERPRETATION: The expression profile of KIR4.1 in glial cells and stage-dependent alterations of KIR4.1 IR in MS lesions are compatible with an immune response against KIR4.1 at least in a subset of MS patients.
OBJECTIVE: Serum antibodies against the glial potassium channel KIR4.1 are found in a subpopulation of multiple sclerosis (MS) patients. Little is known about the expression of KIR4.1 in human normal brain tissue and in MS lesions. METHODS: We analyzed the expression pattern of KIR4.1 in normal brain tissue and MS lesions of the subcortical white matter by immunohistochemistry. Markers of related glial proteins, myelin, and inflammatory cells were analyzed in parallel. RESULTS:KIR4.1 is expressed in oligodendrocytes and astrocytes in the adult human brain. In oligodendrocytes, KIR4.1 appears as a homotetramer channel, in astrocytes as homo- and heterotetramer channels together with KIR5.1. In acute MS lesions, KIR4.1 immunoreactivity (IR) was differentially lost on periplaque oligodendrocytes and perivascular astrocytes. In part of acute lesions, complement activation, apoptotic KIR4.1(+) glial cells, and phagocytes containing KIR4.1(+) fragments accompanied loss of glial KIR4.1 IR. Periplaque reactive astrocytes showed enhanced IR for both KIR4.1 and KIR5.1. In chronic active MS lesions, apart from a general loss of oligodendrocytes in the demyelinated area, we observed a decrease of astroglial KIR4.1 but not glial fibrillary acidic protein IR. In chronic inactive and remyelinating MS lesions, KIR4.1 IR was restored on astrocytes and found in a subset of presumably new myelinating oligodendrocytes. INTERPRETATION: The expression profile of KIR4.1 in glial cells and stage-dependent alterations of KIR4.1 IR in MS lesions are compatible with an immune response against KIR4.1 at least in a subset of MS patients.
Authors: Anne-Katrin Pröbstel; Xiaoyuan Zhou; Ryan Baumann; Sven Wischnewski; Michael Kutza; Olga L Rojas; Katrin Sellrie; Antje Bischof; Kicheol Kim; Akshaya Ramesh; Ravi Dandekar; Ariele L Greenfield; Ryan D Schubert; Jordan E Bisanz; Stephanie Vistnes; Khashayar Khaleghi; James Landefeld; Gina Kirkish; Friederike Liesche-Starnecker; Valeria Ramaglia; Sneha Singh; Edwina B Tran; Patrick Barba; Kelsey Zorn; Johanna Oechtering; Karin Forsberg; Lawrence R Shiow; Roland G Henry; Jennifer Graves; Bruce A C Cree; Stephen L Hauser; Jens Kuhle; Jeffrey M Gelfand; Peter M Andersen; Jürgen Schlegel; Peter J Turnbaugh; Peter H Seeberger; Jennifer L Gommerman; Michael R Wilson; Lucas Schirmer; Sergio E Baranzini Journal: Sci Immunol Date: 2020-11-20
Authors: Olaf Stüve; Clemens Warnke; Krystin Deason; Martin Stangel; Bernd C Kieseier; Hans-Peter Hartung; Hans-Christian von Büdingen; Diego Centonze; Thomas G Forsthuber; Volker Knappertz Journal: Acta Neuropathol Date: 2014-07-04 Impact factor: 17.088
Authors: Adipong Brickshawana; Shannon R Hinson; Michael F Romero; Claudia F Lucchinetti; Yong Guo; Mathias Buttmann; Andrew McKeon; Sean J Pittock; Min-Hwang Chang; An-Ping Chen; Thomas J Kryzer; James P Fryer; Sarah M Jenkins; Philippe Cabre; Vanda A Lennon Journal: Lancet Neurol Date: 2014-07-06 Impact factor: 44.182
Authors: Lucas Schirmer; Dorothy P Schafer; Theresa Bartels; David H Rowitch; Peter A Calabresi Journal: Trends Immunol Date: 2021-02-13 Impact factor: 16.687